Foundation Medicine

Foundation Medicine CEO Michael Pellini

The biotech: Foundation Medicine
Round: $42.5 million
Based: Cambridge, MA
CEO: Michael Pellini
Investors: F. Hoffmann-La Roche, Google Ventures, Kleiner Perkins Caufield & Byers, Third Rock Ventures, Undisclosed Investor, Undisclosed Investor, Undisclosed Investor, Undisclosed Investor

The scoop: The day after we named Foundation Medicine to this year's list of Fierce 15 companies, CEO Michael Pellini unveiled a hefty new round designed to back its commercialization work on FoundationOne, its diagnostic test on the market to evaluate solid tumors. And it has an A-list of drug developers on its partnership roster, putting its technology to work to select ideal patient populations for clinical studies. Only 2 years old, this company is growing fast. And it has some of the coolest venture groups in the business backing its work.

For more:
Special Report: Foundation Medicine - 2012 Fierce 15
Foundation Medicine hauls in $42.5M round to back commercialization effort
Fledgling Foundation Medicine scores a coup with Novartis R&D pact
Foundation Medicine raises $33.5M in expanded Series A

Foundation Medicine
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.